Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 15/20 | 1.00 |
| ▸ | INSR | P06213 | 8/20 | 1.00 |
| ▸ | LCK | P06239 | 3/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 3/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 3/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | IKBKB | O14920 | 1/20 | 1.00 |
| ▸ | CHUK | O15111 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | PAK3 | O75914 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | FES | P07332 | 1/20 | 1.00 |
| ▸ | HCK | P08631 | 1/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 1/20 | 1.00 |
| ▸ | INSRR | P14616 | 1/20 | 1.00 |
| ▸ | FER | P16591 | 1/20 | 1.00 |
| ▸ | FLT4 | P35916 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309890 | 1.00 | IGF1R (1.00) | IGF1RINSRLCKMAPK14AURKB | |
| SCHEMBL311108 | 0.98 | IGF1R (0.97) | IGF1RINSRLCKMAPK14AURKB | |
| SCHEMBL310484 | 0.97 | IGF1R (1.00) | IGF1RINSRLCKMAPK14AURKB | |
| SCHEMBL13226237 | 0.96 | IGF1R (0.92) | IGF1RINSRLCKMAPK14AURKB | |
| SCHEMBL310393 | 0.95 | IGF1R (1.00) | IGF1RINSRLCKMAPK14AURKB | |
| SCHEMBL310380 | 0.94 | IGF1R (1.00) | IGF1RINSRLCKMAPK14AURKB | |
| SCHEMBL310581 | 0.94 | IGF1R (0.88) | IGF1RINSRLCKMAPK14AURKB | |
| SCHEMBL310575 | 0.90 | IGF1R (0.88) | IGF1RINSRLCKMAPK14AURKB | |
| SCHEMBL310192 | 0.90 | IGF1R (0.95) | IGF1RINSRLCKMAPK14AURKB | |
| SCHEMBL310555 | 0.90 | EGFR (0.85) | IGF1RINSRLCKMAPK14AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041293-A1 | AN IGF1R INHIBITOR AND AN AKT INHIBITOR FOR USE IN THE TREATMENT OF CANCER | GENOME RESEARCH LIMITED (GB) | 2025-02-06 | — | — | US | disclosed |
| EP-4475847-A1 | AN IGF1R INHIBITOR AND AN AKT INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Genome Research Limited (GB) | 2024-12-18 | — | — | EP | disclosed |
| CN-119013023-A | IGF1R inhibitors and Akt inhibitors for the treatment of cancer | 基因组研究有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240363249-A1 | Machine Learning Disease Prediction and Treatment Prioritization | AMPEL BIOSOLUTIONS, LLC | 2024-10-31 | — | — | US | disclosed |
| US-20240307414-A1 | METHODS AND MATERIALS FOR TREATING PROSTATE CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2024-09-19 | — | — | US | disclosed |
| US-20240200147-A1 | Non-Small Cell Lung Cancer Diagnosis and Treatment | THE WEST VIRGINIA UNIVERSITY BOARD OF GOVERNORS ON BEHALF OF WEST VIRGINIA UNIVERSITY | 2024-06-20 | — | — | US | disclosed |
| US-20240201203-A1 | COMPOSITIONS AND METHODS FOR TREATING INDIVIDUALS WHO HAVE ONCOGENE-NEGATIVE CANCER | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-06-20 | — | — | US | disclosed |
| US-20240100018-A1 | COMPOUNDS FOR THE TREATMENT OF A DISEASE OR DISORDER, METHODS FOR IDENTIFYING SAID COMPOUNDS | CEDARS-SINAI MEDICAL CENTER | 2024-03-28 | — | — | US | disclosed |
| WO-2023152337-A1 | AN IGF1R INHIBITOR AND AN AKT INHIBITOR FOR USE IN THE TREATMENT OF CANCER | GENOME RESEARCH LIMITED (GB) | 2023-08-17 | — | — | WO | disclosed |
| WO-2022175402-A1 | QUINUCLIDINE-3-ONE DERIVATIVES | APREA THERAPEUTICS AB (SE) | 2022-08-25 | — | — | WO | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-11319376-B2 | Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer | REMD BIOTHERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2022-04-07 | — | — | US | disclosed |
| EP-3954759-A1 | USE OF SMALL MOLECULES TO ENHANCE MAFA EXPRESSION IN PANCREATIC ENDOCRINE CELLS | Janssen Biotech, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041293-A1 | AN IGF1R INHIBITOR AND AN AKT INHIBITOR FOR USE IN THE TREATMENT OF CANCER | IGF1R, IRS1, IGFBP1 | IGF1R 1/4885INSR 13/4885LCK 1047/4885 |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | PNPLA2, LIPC, PNLIP | IGF1R 1934/4885INSR 666/4885LCK 4341/4885 |
| US-20240200147-A1 | Non-Small Cell Lung Cancer Diagnosis and Treatment | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PDCD1, PDCD10 | IGF1R 3468/4885INSR 4270/4885LCK 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.